21 sep: Annual General Assembly
22 sep: Indre værdi af SmallCap Danmark A/S er opgjort til 85,7 kr. pr. ..
21-09-2017 19:39:10

ALK acts on French injunction by accelerating investments in its quality system at the French manufacturing facility

Relateret indhold
16 feb - 
Aktier/åbning: Nordea og DSV tager teten i grønt marked
16 feb - 
Aktier/tendens: DSV får rygklap af storbank før grøn åb..
16 feb - 
ALK-Abelló får japansk godkendelse af allergitablet til..
Relateret debat
10 feb - 
ap69 har jo ellers rost aktien til skyerne, hvor vi sna..
09 feb - 
Det er tænkøligt at den får en kortvarig tur op, men så..
09 feb - 
På det her niveau kan det være relevant at samle op, is..

Copenhagen, 2017-09-21 19:39 CEST (GLOBE NEWSWIRE) --

 

ALK’s 2017 full-year guidance remains unchanged.

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the French National Agency for Medicines and Health Products Safety (ANSM) has issued an injunction against ALK, linked to needed upgrades of the quality system at its manufactoring facility in Vandeuil, France. 

The injunction follows the identification by ALK of an environmental contamination (not a product contamination) in the facility’s sterile production area where injectable SCIT products and skin prick tests for the French market are manufactured. As a result, ALK has temporarily stopped production in the sterile area and halted the release of all products manufactured there. 

ALK and ANSM have been in close dialogue, with the authority carrying out an inspection of the facility in September. In its injunction, the ANSM instructs ALK to make a series of quality improvements to the entire facility, predominantly a strengthening of the environmental monitoring and deviation handling. Furthermore, as a precautionary measure, and in agreement with ANSM, ALK has initiated a recall of all injectable SCIT products released from the affected area since March 2017, regardless of the fact that routine testing of product quality did not reveal any effect from the environmental contamination. The SCIT products that are recalled were only distributed in France. The manufacturing facility in France also produces SLIT-drops, mainly for the French market. SLIT-drops are not affected by the recall. 

ALK’s President and CEO, Carsten Hellmann, says: "We are already investing heavily in equipment upgrades, new systems, digitalisation, and a strengthening of Quality Assurance and Quality Control efforts at our production sites, and the injunction shows that we need to continue these investments. We are committed to rigorously improving the systems and ensuring that we have meticulous training and education in place for our people." 

A plan of action to address ANSM’s instructions is now being put in place and manufacturing in the sterile area will restart once adequate corrective measures have been implemented and verified by the authority. The temporary halt in production will lead to SCIT products and skin prick tests being in short supply until the situation is fully remedied. ALK has informed patients and prescribers in France accordingly. 

The products that are affected by the temporary production suspension represent less than 0.5 percent of ALK’s total, global revenue. At this stage, ALK expects only a limited, negative spill-over effect on sales of other products. Hence, ALK expects that the suspension will have a slightly negative effect on its full-year revenue. Furthermore, ALK expects extra costs associated with the needed upgrade of the quality system. However, ALK’s 2017 full-year guidance remains unchanged.

 

ALK-Abelló A/S

 

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, and South-East Asia, and Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Vedhæftet fil: FM_25_17UK_21092017.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

WDH OPTAKT H2 22/2: Oticon Opn-maskinen skal til eftersyn

19-02-2018 15:42:01
Det helt store spørgsmål på de fleste investorers blokke inden årsregnskabet for 2017 fra William Demant Holding er formentlig, om det trådløse topprodukt inden for høreapparater, Oticon Opn, har kunnet fortsætte med at bidrage til stærk vækst og indtjening i andet halvår.Produktet blev lanceret for godt halvandet år siden og er derfor relativt langt henne i den normale livscyklus for høreapparate..

GN vil have Leo Pharma-topchef ind i bestyrelsen

19-02-2018 14:30:12
Der er lagt op til en enkelt udskiftning i bestyrelsen hos GN Group, når det danske selskab afholder ordinær generalforsamling i hovedkvarteret i Ballerup den 13. marts.Carsten Krogsgaard Thomsen, der er finansdirektør hos NNIT og i øvrigt bror til Mads Krogsgaard Thomsen, der er forskningsdirektør hos Novo Nordisk, har meddelt bestyrelsen, at han ikke ønsker at genopstille.I stedet foreslår GN Gr..

Aktier/middag: Defensive aktier sørger for samlet nedgang til C25

19-02-2018 11:36:39
Mens Mærsk-aktierne stiger forud for tirsdagens kapitalmarkedsdag, så er der fald til flere af de defensive eliteaktier, og det sørger mandag middag for et samlet minus for C25-indekset. Omkring middagstid ligger det danske eliteindeks 0,4 pct. lavere i 1138,49. Holder det dagen hjem, vil det være første gang set over fire handelsdage, at C25-indekset lukker lavere end dagen før.- Der er rimeligt ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Hartmann: Direktør Ulrik Kolding Hartvig død efter cykelulykke
2
Genmab OPTAKT Q4 21/2: 2018-prognosen kommer under lup
3
Aktier/tendens: Mærsk i fokus i ventet positiv åbning
4
Briter har 10 dage til at bruge 1,8 milliarder kroner - citat
5
Novo stævnet sammen med konkurrenter i USA - citat

Relaterede aktiekurser

ALK-Abelló B A/S 731,00 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
20. februar 2018 03:03:43
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180219.1 - EUROWEB2 - 2018-02-20 03:03:43 - 2018-02-20 03:03:43 - 1 - Website: OKAY